Pulmonology最新文献_第10页

Changed profiles of SARS-CoV-2 specific memory T cells in asthmatics with different blood eosinophil counts. 不同血嗜酸性粒细胞计数哮喘患者SARS-CoV-2特异性记忆T细胞谱的变化

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-11-22 DOI: 10.1080/25310429.2024.2424642

Fengming Zhao, Yiting Luo, Bizhou Li, Dengxia Denise Fan, Ziyuan Xiang, Jing Li, Nanshan Zhong, Ruchong Chen

引用次数: 0

Countering antimicrobial resistance. 对抗抗菌素耐药性。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-11-04 DOI: 10.1080/25310429.2024.2411807

B Adhikari, P Parajuli, S Lippmann

引用次数: 0

Impact of treating obesity hypoventilation syndrome on body mass index. 治疗肥胖低通气综合征对体重指数的影响。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-10-24 DOI: 10.1016/j.pulmoe.2023.09.004

R G S Andrade, J F Masa, J-C Borel, L F Drager, P R Genta, B Mokhlesi, G Lorenzi-Filho

{"title":"Impact of treating obesity hypoventilation syndrome on body mass index.","authors":"R G S Andrade, J F Masa, J-C Borel, L F Drager, P R Genta, B Mokhlesi, G Lorenzi-Filho","doi":"10.1016/j.pulmoe.2023.09.004","DOIUrl":"10.1016/j.pulmoe.2023.09.004","url":null,"abstract":"Study objectives: To evaluate the impact of positive airway pressure (PAP) therapy on body mass index (BMI) in patients with obesity hypoventilation syndrome (OHS) associated with obstructive sleep apnea (OSA). Methods: A systematic review using the following terms: \"obesity hypoventilation syndrome\" AND \"treatment\" AND \"randomized\" using Cochrane Central Register of Controlled Trials, Medline and Web of Science was performed from the first data available until February 10, 2023. The inclusion criteria were: (1) original article; (2) adult OHS with concomitant OSA (apnea-hypopnea index or AHI ≥5 events/h); (3) randomized trial with PAP arm and standard care (control); (4) BMI evaluation at baseline and after the first months. We performed an individual participant data meta-analysis of randomized controlled trials.Results: Our initial search retrieved 32 articles and 3 randomized studies fulfilled study criteria and were included in the final analysis, leading to a total of 342 participants. Patients were predominantly females (62%) and had OHS associated with at least mild OSA. As compared to baseline, a decrease in BMI was observed at study endpoint but this difference was not different intergroups (-0.50 ± 1.49 and -0.50 ±1.83, in control and PAP groups respectively (p=0.939)). Weight change was not associate with PAP adherence, OSA severity or use of supplemental oxygen.Conclusions: In contrast to treatment of eucapnic OSA with PAP that is associated with weight gain, treatment of OSA+OHS patients with or without PAP is associated with weight loss. Future studies are necessary to elucidate the mechanism by which weight loss occurs.","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":"2416816"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138300594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoking exposure trajectories and pulmonary function in early adulthood in a Brazilian cohort. 巴西队列中成年早期的吸烟暴露轨迹和肺功能。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2024-10-24 DOI: 10.1016/j.pulmoe.2023.09.005

P Weber, A M B Menezes, H Gonçalves, P D de Oliveira, A Wendt, R Perez-Padilla, F C Wehrmeister

{"title":"Smoking exposure trajectories and pulmonary function in early adulthood in a Brazilian cohort.","authors":"P Weber, A M B Menezes, H Gonçalves, P D de Oliveira, A Wendt, R Perez-Padilla, F C Wehrmeister","doi":"10.1016/j.pulmoe.2023.09.005","DOIUrl":"10.1016/j.pulmoe.2023.09.005","url":null,"abstract":"Objectives: To investigate smoking trajectories and their association with pulmonary function (PF) and respiratory symptoms at age 22.Methods: Data from a population-based cohort study of 3350 individuals and their spirometries were analysed. The outcomes were: forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), forced expiratory flow at the mid expiratory phase (FEF25-75 %), FEV1/FVC and FEF25-75/FVC ratio. Smoking data were collected at perinatal follow-up (gestational exposure) and 15, 18 and 22 years. Group-based trajectory model was applied.Results: Four groups were identified: no exposure (NE), gestational (GE), gestational and adulthood (GAE) and continuous (CE) exposure. Both CE and GAE trajectories were associated with lower values of FEV1/FVC (-1.77pp; p = 0.01 and -1.58 pp; p<0.001 respectively) and FEF25-75/FVC ratio (-7.27pp; p = 0.019 and -6.04pp; p<0.001 respectively) compared to the NE trajectory. Lower FEV1 and FEF25-75 % values were also related to the GAE trajectory (-68 ml; p = 0.03 and -253 ml/s; p<0.001 respectively). Compared to those who never smoked, individuals who smoked 10 or more cigarettes daily presented a reduction in the FEV1/FVC ratio by 1.37pp (p<0.001), FEF25-75 % by 126 ml (p = 0.012) and FEF25-75 %/FVC ratio by 3.62pp (p = 0.011). CE trajectory showed higher odds of wheezing (OR 4.14; p<0.001) and cough (OR 2.39; p = 0.002) compared to the non-exposed group.Conclusions: The in-uterus exposure to maternal smoking reduces PF later in life. However, the perpetuation of smoking behaviour throughout adolescence and early adulthood is determinant for PF main reduction and the emergence of respiratory-related symptoms.","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":" ","pages":"2416818"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71415277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence. Pembrolizumab联合化疗治疗转移性非鳞状NSCLC患者的结果：真实世界证据

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2025-02-05 DOI: 10.1080/25310429.2025.2457856

Irina Surovtsova, Felix J F Herth, Daria B Kokh, Philipp Morakis

{"title":"Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence.","authors":"Irina Surovtsova, Felix J F Herth, Daria B Kokh, Philipp Morakis","doi":"10.1080/25310429.2025.2457856","DOIUrl":"10.1080/25310429.2025.2457856","url":null,"abstract":"Background: Pembrolizumab with chemotherapy (immunochemotherapy) has shown encouraging overall survival (OS) benefits in non-squamous mNSCLC, as demonstrated by the KEYNOTE-189 trial. However, randomised controlled trials may not fully capture the diversity of real-world patients. This study aims to evaluate immunochemotherapy outcomes in a real-world setting, including subgroups underrepresented in the KEYNOTE-189 trial.Methods: Patients diagnosed with non-squamous mNSCLC 2011-2022 and recorded in Cancer Registry Database of the German Federal State Baden-Württemberg (BWCR), were analysed. OS was assessed using Kaplan-Meier and multivariable Cox models, adjusted for major clinical parameters. Results were compared with KEYNOTE-189.Results: Among 2630 eligible cases, 1314 patients received chemotherapy alone and 1316 received immunochemotherapy. Median OS (mOS) was 14.1 months (95%CI: 13.1-15.4) for immunochemotherapy and 10.4 months (95%CI: 9.7-11.2) for chemotherapy alone, with an HR of 0.7 (95%CI: 0.64-0.77). A significant benefit was seen in M1c stage (HR 0.7, 95%CI: 0.63-0.79). No significant OS improvement was observed in patients with ECOG 2-3 or bone metastases.Conclusion: This real-world evidence suggests that immunochemotherapy generally improves OS in mNSCLC. Subgroup analysis showed no survival benefit for patients with ECOG >1 or bone metastasis, but a benefit for patients with M1c stage.","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"31 1","pages":"2457856"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endotoxin exposure associated with respiratory health among European schoolchildren: The SINPHONIE study. 内毒素暴露与欧洲学童呼吸系统健康的关系：SINPHONIE研究。

IF 10.4 2区医学

Pulmonology Pub Date : 2025-12-31 Epub Date: 2025-07-03 DOI: 10.1080/25310429.2025.2511417

Ramen Munir Baloch, Donát Magyar, Peter Rudnai, Tamás Pándics, Zsuzsanna Remény-Nagy, Hanns Moshammer, Hanna Leppänen, Anne Hyvärinen, Martin Täubel, Dan Norbäck, Marta Gabriel, Sara Maio, Sandra Baldacci, Giuseppe Sarno, Giovanni Viegi, Eva Csobod, Eduardo de Oliveira Fernandes, Isabella Annesi-Maesano

{"title":"Endotoxin exposure associated with respiratory health among European schoolchildren: The SINPHONIE study.","authors":"Ramen Munir Baloch, Donát Magyar, Peter Rudnai, Tamás Pándics, Zsuzsanna Remény-Nagy, Hanns Moshammer, Hanna Leppänen, Anne Hyvärinen, Martin Täubel, Dan Norbäck, Marta Gabriel, Sara Maio, Sandra Baldacci, Giuseppe Sarno, Giovanni Viegi, Eva Csobod, Eduardo de Oliveira Fernandes, Isabella Annesi-Maesano","doi":"10.1080/25310429.2025.2511417","DOIUrl":"https://doi.org/10.1080/25310429.2025.2511417","url":null,"abstract":"Background: Evidence on the association between endotoxin exposure and respiratory health in children remains inconsistent, with limited research addressing school environments-key settings for daily exposure. This study investigates the relationship between classroom endotoxin levels and respiratory health among European schoolchildren.Methods: Within the EU-funded SINPHONIE project, endotoxin concentrations were measured in 285 classrooms across 102 schools in 22 European countries. A total of 5,140 children completed a standardized health questionnaire; 4,633 had endotoxin data, 4,170 performed spirometry, and 746 underwent fractioned exhaled nitric oxide (FeNO) testing.Findings: Endotoxin levels varied geographically, with the highest averages in Italy and the lowest in Finland. After adjusting for confounders, exposure to endotoxin levels at or above the median was associated with higher odds of upper and lower respiratory symptoms-runny nose, nasal obstruction, cough, dry throat, breathing difficulty, and feverishness-as well as reduced lung function (p < 0.05). Meta-analysis by WHO European clusters confirmed these associations, though region-specific analyses indicated a possible protective effect of endotoxin exposure in Northern Europe.Interpretation: Findings from SINPHONIE highlight classroom endotoxin as a potential environmental determinant of respiratory health. Reducing exposure in schools-currently an overlooked setting-may support respiratory well-being in children and inform future public health policies.","PeriodicalId":54237,"journal":{"name":"Pulmonology","volume":"31 1","pages":"2511417"},"PeriodicalIF":10.4,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late-onset endobronchial metastasis of oncocytic cell thyroid carcinoma 晚期发生的甲状腺细胞癌支气管内转移。

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/j.pulmoe.2024.02.005

引用次数: 0

Disseminated tuberculosis mimicking pleural mesothelioma in a polycythemia vera patient treated with ruxolitinib 一名接受鲁索利替尼治疗的红细胞增多症患者发生了模仿胸膜间皮瘤的播散性结核病。

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/j.pulmoe.2024.05.003

引用次数: 0

Oral communications 口头沟通

IF 10.4 2区医学

Pulmonology Pub Date : 2024-11-01 DOI: 10.1016/S2531-0437(24)00120-X